December 5, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

M. Marin
312-265-9211
mmarin@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

NetraMark Holdings Inc. (AINMF-OTCQB)

AINMF: Growing Number of Agreements Underscore Expected Benefits of AI De-Risking Solutions for Clinical Research

Billions of dollars are spent on clinical activities to attain regulatory approval for a novel therapy and yet the success rate of ultimately attaining regulatory approval is extremely low. Less than 12% of candidates that commence Phase 1 clinical trials are ultimately approved by the FDA. NetraMark anticipates that its insights potentially could protect millions of dollars of invested capital and potentially shorten the timeline to possible regulatory approval and commercialization.

Current Price (12/4/25)	$0.81
Valuation	**$2.25**

OUTLOOK

NetraMark has signed multiple agreements to help derisk clinical trials and has a growing sales pipeline. These include with CRO Worldwide Clinical Trials; Asklepion Pharmaceuticals; AlgoTherapeutix; a biopharmaceutical company regarding a P3 trial of a novel psychiatric medicine & four contracts with a leading global pharmaceutical company to gain insights into patient subpopulations most/ least likely to benefit from the drug candidates. We believe these position NetraMark for strong revenue advances in FY 2026 going forward.

SUMMARY DATA

52-Week High	**$1.26**
52-Week Low	**$0.57**
One-Year Return (%)	**30**
Beta	**1.59**
Average Daily Volume (sh)	**4,522**
Shares Outstanding (mil)	**81**
Market Capitalization ($mil)	**$80**
Short Interest Ratio (days)	**NA**
Institutional Ownership (%)	**NA**
Insider Ownership (%)	**NA**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2024	**N/A**
P/E using 2025 Estimate	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**Tech-bio**

ZACKS ESTIMATES

Revenue
(in millions of C$)

	Q1 (Dec)	Q2 (Mar)	Q3 (Jun)	Q4 (Sep)	Year (Sep)
2023					0.1 A
2024	0.0 A	0.2 A	0.1 A	0.1 A	0.5 A
2025	0.4 A	0 A	0 A	0 A	0.4 E

EPS / (LPS) (in C$)

	Q1 (Dec)	Q2 (Mar)	Q3 (Jun)	Q4 (Sep)	Year (Sep)
2023					-0.28 A
2024	-0.01 A	-0.01 A	-0.01 A	-0.01 A	-0.05 A
2025	-0.01 A	-0.02 A	-0.02 A	-0.02 E	-0.07 E

Quarters might not sum due to rounding, share counts

Disclosures on page 8 FY end Sept

GROWING NUMBER OF AGREEMENTS

Company's AI technology designed to help optimize drug development clinical trial outcomes…

NetraMark (OTCQB: AINMF) is an Artificial Intelligence (AI) company focused on developing AI and Machine Learning (ML) solutions to support the pharmaceutical industry's ability to optimize clinical research activities. The importance of optimizing clinical activities is seen in industry statistics. Billions of dollars are spent on clinical activities to attain regulatory approval for a novel therapy and yet the success rate of ultimately attaining regulatory approval is extremely low. Specifically, according to McKinsey, "From 2012 to 2022, inflation-adjusted [pharmaceutical] industry R&D spending increased 44 percent, from about $170 billion to $247 billion…" Market research firm Nova One Advisor forecasts that phased clinical trial spending will reach $153.59 billion by 2033, up from an estimated roughly $87 billion in 2024. This would represent a CAGR of 6.49% from 2024 to 2033. The market research firm's projections do not include the significant pre-clinical spending that precedes Phase 1.

Considering the cost and timeline to develop a new drug, bring it to regulatory approval and commercialization (an average 10-15 years at a cumulative investment of $2.6 billion[1]), PhRMA notes that **less than 12% of candidates that commence Phase 1 clinical trials are ultimately approved by the FDA.**

Therefore, we believe there is significant potential for technology that can help derisk and optimize clinical R&D spending. NetraMark anticipates that its insights potentially could protect millions of dollars of invested capital and is leveraging two paths to commercialization – working directly with sponsors, including pharmaceutical companies and partnering with CROs – and in the past few months, the company has signed multiple agreements with midsized pharma companies and a clinical research organization (CRO) and has a growing sales pipeline.

- Worldwide Clinical Trials
- Asklepion Pharmaceuticals
- AlgoTherapeutix
- Biopharmaceutical company regarding a P3 trial of a novel psychiatric medicine
- Four contracts with a leading global pharmaceutical company

In April 2025, NetraMark entered into a non-exclusive global agreement with CRO Worldwide Clinical Trials to introduce a new service offering for Worldwide's customers powered by NetraMark's NetraAI platform to optimize clinical trial efficiencies. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries. Worldwide has about 30 years of clinical experience. Its focus on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease aligns with NetraMark's focus on CNS and the oncology space. The partners expect to use the NetraMark technology across all therapeutic areas and trial phases in the future. Although the onboarding process to become a registered vendor with Worldwide appears to have been longer than originally expected, we believe it positions NetraMark for strong revenue advances in FY 2026 going forward.

Netramark signed a contract with Asklepion Pharmaceuticals to use the NetraAI platform to analyze results from Asklepion's Phase III pediatric clinical trial, CIT-003-01, which evaluated the efficacy of intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects. Asklepion expects NetraMark's AI analytics can help the pharma company demonstrate the benefits of L-citrulline in specific patient subgroups. NetraMark's analysis for Asklepion will focus on identifying subpopulations of patients most likely to benefit from treatment to inform study designs for developing L-citrulline going forward.

---

[1] PhRMA (the Pharmaceutical Research and Manufacturers of America trade association)

NetraMark also announced an agreement with AlgoTherapeutix to use the NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program. AlgoTx is a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN). The NetraAI technology will analyze drug and placebo response variables, among other factors, to inform the design of and optimize future ATX01 trials, with the goal of accelerating development timelines and potentially lowering total costs.

The company also announced partnerships with an unnamed leading biopharmaceutical company to apply NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine and four contracts with an unnamed leading global pharmaceutical firm to support multiple late-stage clinical studies specifically to help identify patient subpopulations that drive treatment response, placebo response, and overall trial variability. By using its technology to analyze data about the subjects participating in a clinical trial, the company can help identify which, if any, patient subpopulations are least likely to benefit from the drug candidate and thereby derisk clinical trials.

The market opportunity within both the CRO and pharma spaces are substantial, with more than 2,800 CROs operating in the U.S. alone, according to ThermoFisher Scientific. Fortune Business Insights puts the value of the global CRO services market at $79.54 billion in 2023 and $86.33 billion in 2024, considering a broad range of services CROs provide in getting a new drug to market, and projects that it will reach $175.46 billion by 2032. In the U.S. alone, Fortune Business Insights projects that the CRO services market will reach $77.80 billion by 2032, with anticipated growth fueled by rising outsourcing of clinical trials by sponsors.



Source: Company presentation

Portfolio of solutions is expanding

The company's product portfolio leverages its proprietary AI, NetraAI, which is designed to help drug developers understand various aspects of their data, including the complexities of patient populations. The company's models improve the understanding of how patients relate to one another and produce insights to help prevent trial failure. The company is also developing expanded capabilities that can provide insights crucial to optimize trial designs and execution.

NetraMark also formed a collaboration with Pentara, a services company that offers clinical data analysis services to the pharmaceutical and biotechnology industries. The two companies intend to launch an intelligence tool to help optimize clinical trial activities using advanced AI-driven anomaly detection to derive a Paradox Risk score. Clinical trials generally are conducted at multiple sites recruiting patients to participate in the trial. The Paradox Risk score expands the company's product offerings. The partners expect it can help drug sponsors and CROs gain insight if certain sites deviate from the overall mean and potentially improve aspects of the trial design, including pre-trial site selection and active trial site reporting, among other potential benefits.

With new solutions under development, NetraMark capabilities will include identifying sites participating in a study that exhibit anomalous participant behavior, as well as the existing tools that identify patient subpopulations that can negatively impact trial results. The company expects this tool can help accelerate its growth and backlog conversion over time, as the CEO recently outlined in a chat with Zacks. The company also recently announced a new collaboration focused on glioblastoma (GBM) research.

CIPM - expected benefits

The company submitted a request for a Critical Path Innovation Meeting (CPIM) with the FDA and has been confirmed for a meeting. NetraMark's objective is to confirm that the methodologies for clinical trial designs of its AI-driven platform align with and are compliant with the goals and expectations of the FDA and other regulatory bodies. The company believes that a CPIM potentially could accelerate its expected growth prospects and facilitate adoption of its technology by potential pharma and CRO partners.

VALUATION

In our view, it is difficult to compare NetraMark shares to those of other companies, as competitors are generally privately-held or do not align directly with the company's technology goals. Although not directly comparable to NetraMark, other AI companies in the healthcare arena and specifically *techbio* could provide some benchmark, in our view. Their shares trade at a wide range of multiples of forward revenue. Given expectations that AI use in the biotech space will rise substantially, the multiples of sales for these companies are generally double digits and reach up to over 68x forward revenue.

We also believe traditional valuation metrics such as P/E or EV/EBITDA are not appropriate measures for AINMF shares at this early stage of the company's development. We value AINMF shares on a price-to-sales (P/S) basis using the company's projected backlog as a proxy for revenue.

We believe the announced contracts, including NetraMark's recent affiliation with Worldwide, provide proof of concept of industry interest in the company's technology. NetraMark expects its contract backlog to reach a projected C$8 million to C$10 million in the next 12 months, or C$9 million / US$6.6 million at the midpoint. Applying a projected P/S multiple of 38x, which represents the lower end of the range of multiples of the few techbio companies trading publicly, we derive a valuation of about $256 million for NetraMark, to which we apply a confidence multiple of 85% to reflect the potential that the company's expectations are too high or timelines slip and that the backlog - revenue recognition lag is greater than we anticipate. On this basis, we derive an adjusted multiple of $217 million or $2.22 per share on the 98 million shares fully diluted. We round up to $2.25 per share.

If backlog ramps faster than we anticipate and / or if the company announces additional partnerships with pharma companies or CROs, our confidence multiple might prove conservative. Conversely, any delay or failure in successful execution of the company's strategy could also represent a potential risk to our valuation and cause the us to lower our confidence metric and potentially cause the share price to decline. We believe the risk / reward ratio could be attractive for investors who have a higher than average risk tolerance and longer time horizon.

RECENT NEWS

- NetraMark signed four contracts with a leading global pharma company on November 18, 2025.
- Netramark signed a contract with a leading biopharma company on November 3, 2025.
- NetraMark and Asklepion Pharmaceuticals announced a contract to use NetraMark technology in Phase III Pediatric Cardiac Study on August 5, 2025.
- On July 30, 2025, NetraMark announced a partnership with Pentara to detect anomalous site and participant behavior.
- NetraMark announced a contract with AlgoTx on July 28, 2025, to enhance clinical trial design for ATX01.
- NetraMark hosted a shareholder business update call on April 10, 2025.
- NetraMark and Worldwide Clinical Trials announced an agreement on April 3, 2025.
- On March 10, 2025, NetraMark raised $1.9 million from warrant exercise.
- NetraMark unveiled AI driven insights for Major Depressive Disorder and Schizophrenia at the ISCTM Conference on March 5, 2025.
- NetraMark and the Ontario Brain Institute partnered to advance AI-powered neuroanalytics for major depression research on February 25, 2025.

RISKS

We believe risks to NetraMark achieving its goals, and to our valuation, include the following, among others.

- Backlog might not grow as quickly as the company expects.
- The company could incur unanticipated costs associated with its initiatives.
- Competition could increase.
- The company might need to raise capital to support its strategy that might be dilutive to current shareholders.
- The uncertain economic outlook could constrain growth or NetraMark's access to growth capital.
- NetraMark could experience delays in closing new contracts that could, in turn, lead to slower than expected revenue ramp.

PROJECTED FINANCIALS

NetraMark Holdings Income Statement & Projections (C$)	Fiscal year ends September 30									
	Dec '23	*Mar*	*Jun*	*Sep*		*Dec '24*	*Mar*	*Jun*	*Sep*	
	1Q24	*2Q24*	*3Q24*	*4Q24*	*2024*	*1Q25*	*2Q25A*	*3Q25A*	*4Q25E*	*2025E*
Sales Revenue	$300	$222,157	$123,092	$110,578	$456,127	$386,085	-	-	-	$386,085
Total Revenue	300	222,157	123,092	110,578	456,127	386,085	-	-	-	386,085
Expenses										
S,G&A	870,297	852,232	773,937	835,371	3,331,837	883,557	1,322,944	1,175,936	1,181,816	4,564,253
Share-Based Compensatio	122,442	85,372	254,105	134,078	595,997	235,595	267,225	184,993	185,918	873,731
Total operating expenses	992,739	937,604	1,028,042	969,449	3,927,834	1,119,152	1,590,169	1,360,929	1,367,734	5,437,984
Operating inc / (loss)	(992,439)	(715,447)	(904,950)	(858,871)	(3,471,707)	(733,067)	(1,590,169)	(1,360,929)	(1,367,734)	(5,051,899)
Other Income / (expense)	139,913	-		-	139,913	-	-			
Pretax loss	(852,526)	(715,447)	(904,950)	(858,871)	(3,331,794)	(733,067)	(1,590,169)	(1,360,929)	(1,367,734)	(5,051,899)
Taxes	-	-	-	-	-	-	-	-	-	-
Net Loss	(852,526)	(715,447)	(904,950)	(858,871)	(3,331,794)	(733,067)	(1,590,169)	(1,360,929)	(1,367,734)	(5,051,899)
LPS	($0.01)	($0.01)	($0.01)	($0.01)	($0.05)	($0.01)	($0.02)	($0.02)	($0.02)	($0.07)
Avg Shares Out	65,873,331	66,222,435	67,615,529	67,521,433	67,427,336	71,838,591	78,133,031	80,893,802	80,894,252	77,939,919

Source: Company reports, Zacks estimates

HISTORICAL STOCK PRICE

Source; Yahoo Finance

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, M. Marin, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.